Hims & Hers Health (HIMS) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.37
- Estimate
- -$0.05
- Surprise
- -640.0%
- Revenue (period 2026-06-30)
- $753.2M
- Score today
- 5.1/10
Revenue source: xbrl.
How the report landed
Hims & Hers Health (HIMS) reported a wider loss than forecast — diluted EPS of -$0.37 against the -$0.05 estimate (a 640.0% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates HIMS Sell at 5.1/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -640.0% surprise compares with a -210.7% four-quarter average. Next scheduled report: 2026-11-09.
What argues against it
- Concentration risk — Geographic: United States
- Target reached (-1.9% upside)
- Risk below floor (2.5 < 3.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $27.82
- Price target
- $33.77
- Stop
- $26.56
- Upside to target
- +21.4%
Model outputs from TrendMatrix’s engine as of 2026-09-06 — shown for context, not personalized investment advice.
HIMS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $6.47B
- P/E (fwd)
- 36.4
- 52-week range
- $13.74–$65.30
- Off 52-week high
- 57.4%
- RSI (14)
- 48
- Volume vs avg
- 0.57×
- Score today
- 5.1/10